

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **SBI HOLDINGS, INC.**

(Incorporated in Japan with limited liability)

(Stock code: 6488)

### **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board

**SBI Holdings, Inc.**

**Yoshitaka Kitao**

*Representative Director,*

*President & Chief Executive Officer*

Japan, 27 December 2013

*As of the date of this announcement, the executive Directors are Mr. Yoshitaka Kitao, Mr. Taro Izuchi, Mr. Takashi Nakagawa, Mr. Tomoya Asakura, Mr. Shumpei Morita, Mr. Noriaki Maruyama and Mr. Peilung Li, the non-executive Directors are Mr. Masato Takamura, Mr. Hiroshi Tasaka and Mr. Teruhide Sato and the independent non-executive Directors are Mr. Masaki Yoshida, Mr. Kiyoshi Nagano, Mr. Keiji Watanabe, Mr. Akihiro Tamaki and Mr. Masanao Marumono.*

27 December 2013  
SBI Holdings, Inc.  
(TOKYO: 8473 / Hong Kong: 6488)

**Notice on Approval for the New Listing of Acucela, a Portfolio Company of  
the SBI Group's Fund, on the Mothers Market of the Tokyo Stock Exchange**

Acucela Inc. (Head Office: Seattle, Washington, U.S.; President, Chairman and Chief Executive Officer: Ryo Kubota; "Acucela"), a clinical-stage biotechnology company that specializes in ophthalmic diseases, in which the SBI Group holds 16.9% (22.8% on a fully diluted basis) of shares as the second largest shareholder, obtained approval for listing on the Mothers market of the Tokyo Stock Exchange as of 27 December 2013.

Accordingly, Acucela is scheduled to be listed on 13 February 2014.

The SBI Group regards IT, biotechnology, and environment and energy as the core fields of the future growth industries, and has achieved an abundant track record in investment and incubation of venture companies in these fields. The Group will continue to proactively focus on developing Japan's next-generation growth industries and increasing the corporate value of the portfolio venture companies.

(Reference)

Outline of Acucela

Acucela Inc. (<http://www.acucela.com/>), established in Seattle in 2002, is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela focuses on developing oral products based on its proprietary visual cycle modulation, or VCM, compounds to address a variety of retinal diseases, primarily age-related macular degeneration, or AMD, diabetic retinopathy, or DR, and diabetic macular edema, or DME, and potentially Stargardt disease, retinitis pigmentosa and retinopathy of prematurity. In addition, Acucela is working on the development of therapeutic agent to treat glaucoma.

\*\*\*\*\*

For further information, please contact:

SBI Holdings, Inc. Corporate Communications Dept., Tel: +81 3 6229-0126